DK1073738T3 - Human K+-ionkanal og terapeutiske applikationer deraf - Google Patents

Human K+-ionkanal og terapeutiske applikationer deraf

Info

Publication number
DK1073738T3
DK1073738T3 DK99920731T DK99920731T DK1073738T3 DK 1073738 T3 DK1073738 T3 DK 1073738T3 DK 99920731 T DK99920731 T DK 99920731T DK 99920731 T DK99920731 T DK 99920731T DK 1073738 T3 DK1073738 T3 DK 1073738T3
Authority
DK
Denmark
Prior art keywords
nucleic acid
ion channel
methods
present
relates
Prior art date
Application number
DK99920731T
Other languages
English (en)
Inventor
Walter Stuehmer
Synnoeve Beckh
Camino Fernandez-Miranda D Del
Ruediger Weseloh
Luis Angel Pardo-Fernandez
Andrea Brueggemann
Perez Araceli Sanchez
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Application granted granted Critical
Publication of DK1073738T3 publication Critical patent/DK1073738T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK99920731T 1998-04-21 1999-04-21 Human K+-ionkanal og terapeutiske applikationer deraf DK1073738T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98107268 1998-04-21
PCT/EP1999/002695 WO1999054463A2 (en) 1998-04-21 1999-04-21 Human k+ ion channel and therapeutic applications thereof

Publications (1)

Publication Number Publication Date
DK1073738T3 true DK1073738T3 (da) 2005-01-24

Family

ID=8231794

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99920731T DK1073738T3 (da) 1998-04-21 1999-04-21 Human K+-ionkanal og terapeutiske applikationer deraf

Country Status (10)

Country Link
US (7) US6638736B1 (da)
EP (1) EP1073738B1 (da)
JP (2) JP2002512029A (da)
AT (1) ATE278017T1 (da)
CA (1) CA2323571A1 (da)
DE (1) DE69920681T2 (da)
DK (1) DK1073738T3 (da)
ES (1) ES2230852T3 (da)
PT (1) PT1073738E (da)
WO (1) WO1999054463A2 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1073738B1 (en) * 1998-04-21 2004-09-29 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. Human k+ ion channel and therapeutic applications thereof
DE10025620A1 (de) * 2000-05-24 2001-12-06 Forschungsgesellschaft Genion Verfahren zur Herstellung von Chimären zwischen bakteriellen und eukaryotischen Kaliumkanälen auf festen Trägern und deren Verwendung zur Identifizierung von Kaliumkanalagonisten und -antagonisten
DE10224534A1 (de) * 2002-05-31 2003-12-11 Juergen Dolderer Verfahren zum Diagnostizieren des colorektaien Karzinoms in einer Gewebeprobe und Mittel zur Behandlung
CA2582683A1 (en) * 2004-10-01 2006-04-13 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Novel antibodies directed to the mammalian eag1 ion channel protein
WO2006037611A2 (en) * 2004-10-01 2006-04-13 Centro De Investigación Y De Estudios Avanzados Del Ipn Methods for the early diagnosis of viral infections, inflammatory diseases, a predisposition for proliferative disorders or hyperplasia by analysing eag or erg expression levels
AU2013201604B2 (en) * 2007-04-13 2014-08-14 Southern Research Institute Anti-angiogenic agents and methods of use
ES2334084B1 (es) * 2007-12-21 2011-01-24 Inst Cientifico Tecnol Navarra Marcadores geneticos para el pronostico de la esclerosis multiple.
US8892184B2 (en) 2010-10-18 2014-11-18 Siemens Medical Solutions Usa, Inc. Systems and methods for reducing interference in a dual modality imaging system
TWI570415B (zh) * 2015-10-02 2017-02-11 A spring probe having an outer sleeve and a probe device having the spring probe
EP3195727A1 (en) 2016-01-22 2017-07-26 Forschungsinstitut Fur Biologischen Landbau (FiBL) Duddingtonia flagrans strain and feed additive formulation for biological pest control

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) * 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
GB9303210D0 (en) 1993-02-17 1993-03-31 Univ Manitoba Cancer treatment
DE69120430D1 (de) 1990-12-18 1996-07-25 Wellcome Found Mittel zur verstaerkung der wirkung von antitumoralen mittel und zur widerstandsbekaempfung von vielfachdrogen
WO1998000168A1 (en) * 1996-07-02 1998-01-08 Novartis Consumer Health S.A. Topical composition comprising a combination of antihistaminic compounds with terpenoid compounds
US6610827B1 (en) * 1997-10-29 2003-08-26 Elan Pharmaceuticals, Inc. Potassium channel subunit polypeptide and polynucleotide compositions and uses therefor
EP1073738B1 (en) * 1998-04-21 2004-09-29 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. Human k+ ion channel and therapeutic applications thereof

Also Published As

Publication number Publication date
WO1999054463A3 (en) 2000-04-20
WO1999054463A2 (en) 1999-10-28
US7129207B2 (en) 2006-10-31
US6638736B1 (en) 2003-10-28
PT1073738E (pt) 2005-01-31
DE69920681T2 (de) 2005-09-08
US20030092120A1 (en) 2003-05-15
US7314914B2 (en) 2008-01-01
US20030087378A1 (en) 2003-05-08
US20030077735A1 (en) 2003-04-24
ATE278017T1 (de) 2004-10-15
JP2009235091A (ja) 2009-10-15
JP2002512029A (ja) 2002-04-23
EP1073738B1 (en) 2004-09-29
DE69920681D1 (de) 2004-11-04
US20030087377A1 (en) 2003-05-08
US7364845B2 (en) 2008-04-29
CA2323571A1 (en) 1999-10-28
US20100021467A1 (en) 2010-01-28
US7364730B2 (en) 2008-04-29
US20080020406A1 (en) 2008-01-24
EP1073738A2 (en) 2001-02-07
ES2230852T3 (es) 2005-05-01

Similar Documents

Publication Publication Date Title
Zeng et al. ALK is a therapeutic target for lethal sepsis
Nakatsuji et al. A commensal strain of Staphylococcus epidermidis protects against skin neoplasia
Terenzio et al. Locally translated mTOR controls axonal local translation in nerve injury
Tam et al. An unusual structural motif of antimicrobial peptides containing end-to-end macrocycle and cystine-knot disulfides
Kummer et al. Inflammasome components NALP 1 and 3 show distinct but separate expression profiles in human tissues suggesting a site-specific role in the inflammatory response
Kuriakose et al. Diminazene aceturate (Berenil) modulates LPS induced pro-inflammatory cytokine production by inhibiting phosphorylation of MAPKs and STAT proteins
Lv et al. Scutellarin inhibits hypoxia‐induced epithelial‐mesenchymal transition in bladder cancer cells
Pal et al. Ubiquitin-specific proteases as therapeutic targets for the treatment of breast cancer
BR0312913A (pt) Ativo de biciclo-pirazóis como inibidores de cinase, processo para sua preparação e composições farmacêuticas compreendendo o mesmo
BR0009505A (pt) Compostos e processos para terapia e diagnóstico de câncer de pulmão
Ko et al. Crude preparations of Helicobacter pylori outer membrane vesicles induce upregulation of heme oxygenase-1 via activating Akt-Nrf2 and mTOR–IκB kinase–NF-κB pathways in dendritic cells
DK0836485T3 (da) Kaskade-polymer-komplekser, fremgangsmåde til deres fremstilling og farmaceutiske midler indeholdende disse
ATE389724T1 (de) Menschliche dnase i hyperaktive varianten
Shou et al. Type I interferons exert anti-tumor effect via reversing immunosuppression mediated by mesenchymal stromal cells
DK1073738T3 (da) Human K+-ionkanal og terapeutiske applikationer deraf
RU2768186C2 (ru) Комбинированные лекарственные средства, содержащие модуляторы pkm2 и hmgb1
Philipp et al. Radiation-induced endothelial inflammation is transferred via the secretome to recipient cells in a STAT-mediated process
BRPI0407544A (pt) derivados de pirazol tetracìclicos como inibidores da cinase, processo para a sua preparação e composições farmacêuticas que os compreendem
Welk et al. Proteasome activator PA200 regulates myofibroblast differentiation
Chen et al. Knocking out SST gene of BGC823 gastric cancer cell by CRISPR/Cas9 enhances migration, invasion and expression of SEMA5A and KLF2
Whitley et al. ENTPD1 (CD39) expression inhibits UVR-induced DNA damage repair through purinergic signaling and is associated with metastasis in human cutaneous squamous cell carcinoma
Liu et al. MicroRNA‐936/ERBB4/Akt axis exhibits anticancer properties of gastric cancer through inhibition of cell proliferation, migration, and invasion
Chen et al. Gelsevirine is a novel STING-specific inhibitor and mitigates STING-related inflammation in sepsis
CA2033249C (en) Cytostatic or cytotoxic combination of active substances for use in therapeutic procedures
EE200200049A (et) Polümorfismid inimese MDR-1 geenis ning nende kasutamine diagnostikas ja terapeutilistes rakendustes